Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$13.19
-0.8%
$15.28
$13.12
▼
$33.09
$1.24B0.216,934 shs1,733 shs
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$45.57
-0.3%
$49.57
$22.07
▼
$72.36
$1.36B0.7656,459 shs140,876 shs
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
$22.12
-1.7%
$22.04
$15.76
▼
$38.33
$1.37B1.52437,796 shs90,055 shs
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
$13.57
-7.4%
$10.99
$7.20
▼
$45.00
$333.39M-0.04142,990 shs43,587 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
-9.10%-13.48%-13.53%-26.46%-61.25%
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-1.12%-4.67%-1.89%-22.48%+35.22%
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
+4.17%-6.52%+22.02%-29.25%-16.14%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
+2.45%-4.99%+80.42%-7.22%-13.47%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$13.19
-0.8%
$15.28
$13.12
▼
$33.09
$1.24B0.216,934 shs1,733 shs
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$45.57
-0.3%
$49.57
$22.07
▼
$72.36
$1.36B0.7656,459 shs140,876 shs
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
$22.12
-1.7%
$22.04
$15.76
▼
$38.33
$1.37B1.52437,796 shs90,055 shs
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
$13.57
-7.4%
$10.99
$7.20
▼
$45.00
$333.39M-0.04142,990 shs43,587 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
-9.10%-13.48%-13.53%-26.46%-61.25%
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-1.12%-4.67%-1.89%-22.48%+35.22%
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
+4.17%-6.52%+22.02%-29.25%-16.14%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
+2.45%-4.99%+80.42%-7.22%-13.47%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
3.15
Buy$43.44229.37% Upside
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.69
Moderate Buy$75.6766.04% Upside
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
3.00
Buy$46.38109.65% Upside
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
2.78
Moderate Buy$40.00194.70% Upside

Current Analyst Ratings Breakdown

Latest LYEL, DMRA, AAPG, and ANAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
Reiterated RatingBuy$48.00
11/13/2026
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
Lower Price TargetBuy$45.00 ➝ $39.00
11/6/2026
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
Initiated CoverageBuy$60.00 ➝ $59.00
11/4/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Reiterated RatingSell (E+)
11/3/2026
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
Reiterated RatingBuy$44.00
10/16/2026
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
Initiated CoverageOutperform
10/15/2026
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
Reiterated RatingSell (D-)
10/14/2026
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
Initiated CoverageBuy$46.00
10/13/2026
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
Initiated CoverageOutperform ➝ Buy$46.00
10/13/2026
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
Initiated CoverageMarket Outperform$35.00
10/8/2026
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
Lower Price TargetOverweight$46.00 ➝ $33.00
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$82.10M15.06N/AN/A$2.04 per share6.47
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$232.39M5.86N/AN/A$1.34 per share34.01
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
N/AN/AN/AN/A$5.91 per shareN/A
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
$40K8,344.00N/AN/A$7.84 per share1.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
-$177.71MN/AN/AN/AN/AN/AN/AN/AN/A
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$13.23M$4.969.1918.83N/A96.30%-14.28%-1.03%N/A
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
-$209.84M-$1.41N/AN/AN/AN/A-122.16%-62.32%N/A
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-$274.45M-$12.56N/AN/AN/A-1,701,066.75%-107.62%-80.01%N/A

Latest LYEL, DMRA, AAPG, and ANAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q1 2027
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$1.84$0.11+$1.95$0.11$25.56 million$30.27 million
11/4/2026Q3 2026
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
-$0.52-$0.40+$0.12-$0.40N/AN/A
11/4/2026Q3 2026
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-$2.0063-$1.86+$0.1463-$1.6890$0.00 million$0.00 million
9/21/2026Q2 2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$0.4650$5.11+$5.5750$5.11$14.06 million$27.49 million
8/19/2026H1 2026
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/A-$0.65N/A-$0.6450N/A$22.24 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/AN/AN/AN/AN/A
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
N/AN/AN/AN/AN/A
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
1.09
1.22
1.18
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
7.58
7.58
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
N/A
14.80
14.80
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
N/A
4.02
4.02
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
76793.74 millionN/AN/A
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10429.90 million20.37 millionOptionable
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
4061.90 million61.66 millionNo Data
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
16124.59 million23.06 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascentage Pharma Group International stock logo

Ascentage Pharma Group International NASDAQ:AAPG

$13.19 -0.10 (-0.75%)
As of 10:50 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

AnaptysBio stock logo

AnaptysBio NASDAQ:ANAB

$45.57 -0.16 (-0.35%)
As of 11:02 AM Eastern
This is a fair market value price provided by Massive. Learn more.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Damora Therapeutics, Inc. Common Stock stock logo

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

$22.12 -0.38 (-1.69%)
As of 10:44 AM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Lyell Immunopharma stock logo

Lyell Immunopharma NASDAQ:LYEL

$13.57 -1.08 (-7.35%)
As of 11:02 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.